NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,425.70 -12.80 (-0.52%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,789.24 -56.06 (-0.10%)
ORIC May 2024 2.500 call
| Previous close | 10.90 |
| Open | 10.90 |
| Bid | 10.50 |
| Ask | 15.00 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 10.90 - 10.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
Simply Wall St.We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
GlobeNewswireORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-class profile with strong pharmacokinetic, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer Presented updat
- GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2024 (the “Grant Date”), ORIC granted a total of 14,500 non-qualified stock options and 2,300 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2024. These inducement grants were granted
